Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox + deferiprone versus deferoxamine + deferiprone for iron overload in transfusion-dependent beta-thalassemia
IRCT20190106042262N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in beta thalassemia and transfusional hemosiderosis comparing Deferasirox + deferiprone with Deferoxamine + deferiprone (2 arms). Primary endpoints: Heart MRI T2*, Liver MRI T2* and 3 more. Started Feb 2018; status: completed.
02
Drugs
deferasiroxdeferipronedeferoxamine
03
Conditions
beta thalassemiatransfusional hemosiderosis
Beyond the preview
Go deeper on IRCT20190106042262N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190106042262N1.